Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. 1 The poor prognosis of patients with NSCLC is associated with several factors, among which are late disease diagnosis and the small number of effective drugs. The absence of validated prognostic biomarkers could also be relevant, because even patients with stage I NSCLC who undergo potentially curative surgical resection are at high risk of dying from recurrent disease, with a 5-year relapse rate of 35% to 50%. 1 Although adjuvant platinum-based chemotherapy is beneficial in more advanced resected disease, in which most of the patients have a high risk of recurrence, [2] [3] [4] [5] [6] it has failed to show a survival benefit for patients at stage I. 7, 8 One explanation for these negative data in the early stages could be the lack of biologic factors predicting their recurrence and the fact that, in the absence of useful biomarkers, all stage I NSCLCs are pooled, making it more difficult to draw meaningful clinical conclusions.
In the search for new potential biomarkers of human cancer, the hypermethylation of the CpG island sequences located in the promoter regions of tumor suppressor genes are gaining prominence. adjuvant chemotherapy in the expanding population of those diagnosed with early-stage lung cancer.
PATIENTS AND METHODS

Study Design and Patient Population
Patients were eligible to enter the study as part of either discovery or validation cohorts if they underwent surgical resection of NSCLC in any of the international participating institutions. Patients treated with neoadjuvant therapy and/or patients with large cell-carcinoma were not included in the study. The clinical characteristics of the NSCLC surgical samples obtained are provided in Table 1 . Descriptors of the patients by site of origin and for each single case are included in the Data Supplement. Tumors were collected by surgical resection from patients who provided consent and under approval by the institutional review boards. The median clinical follow-up was 7.2 years. Follow-up was performed by using radiographic imaging (chest x-ray and computed tomography scans), and time of recurrence was noted. In addition, 25 histologically normal lung tissue counterparts without any histologic evidence of malignancy were also analyzed (Data Supplement). The NSCLC tumor samples were studied in a consecutive manner as they arrived at the centralized DNA methylation facility and passed the technical quality checks.
Procedures
The DNA methylation status of 450,000 CpG sites was established by using the Infinium 450K Methylation Array.
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Statistical Analysis
Assay results were compared with patient outcomes in a double-blind manner. Median follow-up duration was calculated according to the inverse Kaplan-Meier method. Differences in distributions between groups were examined by the 2 test. The Kaplan-Meier method was used to estimate RFS, and differences among the groups were analyzed with the log-rank test. Hazard ratios (HRs) from univariate Cox regression analysis were used to determine the association of clinicopathologic features with relapse. Multivariate Cox proportional hazards regression was used to evaluate independent prognostic factors associated with RFS.
RESULTS
Characteristics of Patients in the Discovery Cohort
Clinical characteristics of the 444 patients in the discovery cohort are listed in Table 1 . Descriptors of the patients by site of origin and for each single case are shown in the Data Supplement. The clinicopathologic characteristics of the lung tumors studied were related to the site of origin (United States v Europe).
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DNA Methylation Profiles Identify Two Groups With Different RFS Rates
We first evaluated a genome-wide DNA methylation profile of the original cohort of 444 patients with lung tumors, which included two NSCLC subtypes (adenocarcinoma and squamous cell carcinomas) by using a previously validated 450,000 CpG methylation microarray. 12, 13 In addition, 25 histologically normal lung tissue counterparts without any histologic evidence of malignancy were also analyzed (Data Supplement).
The analyses of CpG methylation ␤ values from the DNA methylation microarray within all primary NSCLCs (n ϭ 444) and histologically normal tissues (n ϭ 25) identified 10,000 promoter CpGs with the most variable CpG methylation levels (Data Supplement). These 10,000 top-ranked CpG sites were plotted in an unsupervised manner in the 444 primary NSCLCs (Fig 1A) . The hierarchical clustering distinguished two main types of tumors that accounted for 70 (16%; group A) and 374 (84%; group B) patients. The 2 tests showed a significantly higher proportion of the adenocarcinoma histologic type in group A ( 2 test P ϭ .02), but no other significant differences in the distribution of the tumors according to stage, sex, or smoking history between group A and group B were observed (Data Supplement).
We investigated whether these two DNA methylation groups had any effect on the RFS of these patients. We analyzed the subset of patients who had undergone resection of NSCLC and had not received adjuvant chemotherapy before relapse, because of the possible confounding effect of chemotherapy on the RFS. Overall survival was not selected as an end point for the study because it could be affected by subsequent therapies received at relapse. Overall, 198 patients with NSCLC met the criteria for inclusion in the RFS cohort. Most importantly, these group A patients with NSCLC had a significantly shorter RFS, as shown in the Kaplan-Meier survival analysis (log-rank test P Ͻ .001; Fig 1B) and in the univariate (HR, 2.45; P Ͻ .001) and multivariate (HR, 2.40; P Ͻ .001) Cox regression analyses of stage, histology, smoking history, age, and sex (Data Supplement). In reference to histology, the unsupervised clustering analysis of either adenocarcinomas or squamous cell carcinomas also identified a group associated with shorter RFS (HR, 2.47; P ϭ .002 and HR 4.93; P ϭ .001, respectively; Data Supplement).
We wanted to extend these observations to identify those NSCLC tumors that, despite their low stage, are prone to recurrence. The selection of these patients is critical because approximately 30% to 40% of patients with stage I NSCLC die of recurrent disease.
19-21 To address this, the profile of the aforementioned 10,000 promoter CpGs, which had already shown their prognostic value throughout all NSCLC stages, was plotted in an unsupervised manner in the 237 patients with stage I NSCLC (Fig 1C) . Hierarchical clustering distinguished two main types of tumors, accounting for 63 (27%; group 1) and 174 (73%; group 2) patients. The 2 tests revealed no significant differences in the distribution of the tumors in the two groups by sex, smoking history, and histologic type (Data Supplement). Among the 237 patients with stage I NSCLC, 147 met the described criteria for inclusion in the RFS cohort. The ineligible patients (n ϭ 90) did not show a higher recurrence rate ( 2 test P ϭ .12). Group 1 identified patients with high-risk stage I NSCLC that had lower RFS, as revealed by the Kaplan-Meier survival analysis (log-rank test P ϭ .03; Fig 1D) and in the univariate (HR, 1.85; P ϭ .037) and multivariate (HR, 2.35; P ϭ .004) Cox regressions of histology, smoking history, age, and sex (Data Supplement). In reference to histology, the unsupervised clustering analysis of the adenocarcinomas in stage I also identified a group associated with shorter RFS (HR, 2.94; P ϭ .003; Data Supplement), and a trend was observed for squamous cell carcinomas (HR, 2.55; P ϭ .09; Data Supplement). We also performed a Cox analysis that included smoking pack-years as a covariate. We categorized packyears 22 as less than 30 or Ն 30. The inclusion of the pack-year data value did not change the significant association of group 1 tumors with shorter RFS (HR, 2.3; P ϭ .007). For all the patients with stage I NSCLC (because stage IA and IB have different outcomes), we also added this particular feature (according to the sixth revision of the TNM classification criteria) to the Cox regression multivariate analysis and group 1 remained significantly associated with shorter RFS (HR, 2.12; P ϭ .018). The inclusion of tumor size within stage I (also an indicator of poor prognosis in NSCLC) in the Cox analysis did not alter the significant association of group 1 tumors with shorter RFS (HR, 2.02; P ϭ .05). The reclassification of the stage I tumors according to the seventh revision of the TNM classification criteria also confirmed that group 1 patients remained significantly associated with shorter RFS (HR, 2.14; P ϭ .05).
Identification of Candidate Genes as DNA Methylation Biomarkers of Shorter RFS in the Discovery Cohort of Stage I NSCLC
The identification of a DNA methylation signature for stage I NSCLC that predicts early recurrence might be useful, but the finding of a smaller panel of DNA methylation biomarkers could simplify the process. To achieve this goal, we developed an integrative approach to rank the CpG sites that, according to their methylation status (␤ values), were best at discriminating the 444 NSCLC samples from the 25 histologically normal lung tissue samples. This analysis identified 338 highly ranked CpG sites (Data Supplement). From these, we focused on the CpGs located in regulatory regions: promoter CpG islands 9-11 and shores. 23, 24 We found that 150 of the 338 CpG sites were located in the described regions. All of these 150 CpG sites were present in the 10,000 CpG sites used in the clustering. CpG hypermethylation of these 150 sites was significantly enriched in group A versus group B (t test P Ͻ .001) and in group 1 versus group 2 (t test P Ͻ .001), supporting their potential prognostic value. Thus, we tested the methylation value of each of these 150 CpG sites for RFS in the 147 stage I tumors by Kaplan-Meier survival and multivariate Cox regression. We identified 54 CpGs corresponding to 42 genes that were significantly associated with shorter RFS at a 10% false discovery rate (Data Supplement). Our data mining approach can be complemented by others and, in this regard, the promoter CpG sites of other methylation markers in lung cancer 25 did not pass the criteria used. However, we confirmed that CDH13 and RASSF1A hypermethylation was associated with shorter RFS (HR, 3.47; P ϭ .01 and HR, 2.17; P ϭ .02, respectively) in the 147 stage I tumors.
Validation of Candidate Genes as DNA Methylation Biomarkers of Shorter RFS in an Independent Cohort of Stage I NSCLC
Once we had identified 42 genes with CpG promoter methylation that influenced RFS in our initial discovery cohort of 147 stage I tumors, we sought to validate these single DNA methylation markers in an additional cohort of 143 patients with stage I NSCLC ( Table 1) . Descriptors of the patients by site of origin and for each single sample are shown in the Data Supplement. All these new NSCLC samples were obtained from patients who had undergone a resection and did not receive adjuvant chemotherapy. The validation cohort, in comparison to the discovery set, was significantly enriched in European samples and, thus, in affected men and squamous cell carcinomas. 16, 17 The methylation levels at the described CpG sites were analyzed by pyrosequencing 15 to test a more affordable large-scale approach. Methylation value by pyrosequencing was obtained from the average of each of the CpG dinucleotides included in the sequence analyzed (Data Supplement). Because the DNA material was limited, we selected the top 10 genes (Data Supplement) with an HR of more than
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Of these 10 candidate DNA methylation biomarkers associated with recurrence in the discovery cohort by using the DNA methylation microarray, five (50%) were significantly associated with recurrence (P Ͻ .05) in the validation cohort of 143 stage I NSCLC samples analyzed by pyrosequencing. These were the genes histone cluster1 H4F (HIST1H4F; HR, 3.55; P Ͻ .001), protocadherin gamma subfamily B6 (PCDHGB6; HR, 2.95; P ϭ .002), neuropeptide B/W receptor 1 
Time Since Surgery (years) (NPBWR1; HR, 2.71; P ϭ .004), ALX homeobox protein 1 (ALX1; HR, 2.29;Pϭ.015),andhomeoboxA9(HOXA9;HR,2.03;Pϭ.027;Fig2and Data Supplement). In addition, three other genes (30%) showed a trend toward significance (OTX2; HR, 1.82; P ϭ .11; TRIM58; HR, 1.57; P ϭ .14; and TRH; HR, 4.23; P ϭ .17; Data Supplement). The pyrosequencing values for the five significant genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9) in all studied samples, histologically normal tissues (n ϭ 25), and primary NSCLC (n ϭ 143) are provided in the Data Supplement.
We also observed a greater risk of shorter RFS, according to KaplanMeier plots, when stage I NSCLCs harbored a large number of the five statistically significant hypermethylated markers (HIST1H4F,  PCDHGB6, NPBWR1, ALX1, and HOXA9) . To obtain the most useful methylation signature, we chose the cutoff of zero to one versus two or more hypermethylated markers, because it was the best one in resembling the percentage of expected recurrences. 1, [19] [20] [21] The described methylation signature divides the patients with stage I tumors into two arms: patients with zero to one methylated markers that show longer RFS and those with two or more hypermethylated genes that were associated with a higher risk of poor RFS by Kaplan-Meier estimates (Fig 3A) . The heavily hypermethylated group identified patients with high-risk stage I NSCLC who had shorter RFS, as shown by the Kaplan-Meier survival analysis (logrank test P ϭ .010; Fig 3A) stage I tumors were subdivided into IA and IB according to the sixth revision of the TNM classification (HR, 3.09; P ϭ .002). The reclassification of the stage I tumors according to the seventh revision of the TNM classification criteria also confirmed the relevance of the enriched hypermethylationgroupforshorterRFSin103originalstageItumorsforwhich all the necessary clinicopathologic information was available (HR, 2.89; P ϭ .010). The inclusion of tumor size in the Cox analysis within stage I did not alter the significant association of tumors with two or more methylated markers with shorter RFS (HR, 2.88; P ϭ .011). Because 80% of recurrences of stage I NSCLC occur within 3 years of surgery, 19 we also calculated how many patients relapsed in this period. We observed that 48% (95% CI, 39.8% to 56.4%) of patients from the enriched methylated group relapsed, but only 18% (95% CI, 16.1% to 19.5%) of those in the low methylated group (zero to one methylated markers). Finally, as expected, the prognostic zero to one versus two or more hypermethylated genes signature obtained by pyrosequencing in the validation cohort was alsoobservedinthe147stageINSCLCsfromthediscoverycohortstudied bytheDNAmethylationmicroarray(HR,1.95; Pϭ.023;Fig3B) .Overall, we have identified DNA methylation classifiers that, at a different level of resolution, are potential prognostic biomarkers of shorter RFS in stage I NSCLC (Fig 3C) .
DISCUSSION
One challenge in lung cancer management is that, despite complete surgical resection, patients with early-stage NSCLC are at considerable risk of recurrence and death. For this reason, we studied samples from stage I patients with the aim of identifying candidate DNA methylation biomarkers that can distinguish between patients at low risk of relapse and those at high risk for whom adjuvant treatment could be prescribed. Our results have distinguished two prognostic groups of stage I NSCLC at two levels of resolution by using a DNA methylation microarray profile that includes 10,000 CpG sites and by obtaining a methylation signature based on five genes derived from Cox regression models that could simplify the decision-making process.
Our study represents the largest cohort of primary NSCLCs studied for high-resolution DNA methylation analyses with a clinical orientation, a complement to the genomics 26 and expression 27 data. Other genomic approaches with lower resolution have determined DNA methylation profiles in NSCLCs, 15,28-32 although they have not focused on stage I. Candidate gene approaches have also suggested DNA methylation markers that are linked with prognosis in NSCLC.
25,33 An example is provided by the suggested association between p16INK4a, CDH13, RASSF1A, and APC hypermethylation and early recurrence in stage I lung cancer. 25 In addition, some CpG methylation events may be associated with better prognosis, 34 and their identification will require further analyses. It is also noteworthy to explain that useful hypermethylated markers to add to those characterized herein are possible and can be obtained from further mining of our publically available DNA methylation data.
Among the genes in our five-gene methylation signature, HOXA9 hypermethylation has been described in lung tumorigenesis. 29, 35, 36 Although the association of HOXA9 methylation with RFS was not assessed, HOXA9 hypermethylation relates to poor prognosis in other tumor types. 37, 38 For the other genes, PCDHGB6 and NPBWR1 hypermethylation occur in breast 39 and prostate 40 cancer, respectively, and both are associated with poor prognosis. Although our analysis was not aimed at finding markers of chemoresponse, the observed CpG hypermethylation of a particular histone gene in the high-risk group (HIST1H4F) warrants further research because a small subset of patients with NSCLC are sensitive to histone deacetylase inhibitors. 41 The identified patients with lung cancer whose high risk is associated with the described DNA methylation markers might also be a candidate group to receive DNA demethylating agents. 42 The introduction of new therapies in NSCLC, such as epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors, is a promising avenue for improving the outcome of these patients, but the target population is small. Although surgery remains the reference treatment in stage I NSCLCs, recurrence of the disease still occurs. Adjuvant platinum-based chemotherapy is beneficial in stage II and IIIa NSCLC.
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Most studies have failed to show a survival benefit for adjuvant chemotherapy in stage I, 7,8 although a trend was observed for stage IB. 7,8 However,nomolecularbiomarkerswereinvestigatedinthosetrials.Ifwecould identify stage I NSCLCs associated with shorter RFS, we could design stage-specific clinical trials in which a benefit of adjuvant therapies could accrue to the high-risk population. The DNA methylation markers identified herein, once they have been externally validated, could be useful for generating treatment guidelines for early-stage lung tumors.
